About: KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, the expression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1 alpha, KRAS, mTOR, MT1A, MT2A, NF-kappa B1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher. Zinc(II) ions are important components of many proteins and are involved in numerous cellular processes such as apoptosis or drug resistance. Prostate cancer has a unique relationship with zinc(II) ions. However, the relationship was examined only in short-term zinc(II) treatments. Therefore, the aim of this study was to create zinc-resistant prostatic cell lines at various stages of the disease (22Rv1 and PC-3) and a normal prostate epithelium (PNT1A) using a long-term zinc exposure. Consequently, the expression profile of the following genes was analyzed: BAX, Bcl-2, Beclin-1, CFLAR, HIF1 alpha, KRAS, mTOR, MT1A, MT2A, NF-kappa B1, p53, survivin, ZIP1, ZnT-1. The resistance was verified using the MTT test; on average a 1.35-fold lower zinc(II) toxicity (higher IC50) was determined in zinc(II)-resistant cells. The associated resistance to cisplatin was also determined; IC50 for cisplatin was 1.52-fold higher. (en)
Title	KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer (en)
skos:prefLabel	KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer KRAS NF-kappa B is involved in the development of zinc resistance and reduced curability in prostate cancer (en)
skos:notation	RIV/00216224:14110/14:00076568!RIV15-MSM-14110___
http://linked.open...avai/riv/aktivita	O S V
http://linked.open...avai/riv/aktivity	O, S, V
http://linked.open...iv/cisloPeriodika	7
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Holubová, Monika Axmanová, Martina Raudenská, Martina Gumulec, Jaromír Sztalmachová, Markéta Masařík, Michal
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	25134
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/14:00076568
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	CITRATE METABOLISM; EPITHELIAL-CELLS; CARCINOMA-CELLS; DNA-DAMAGE; T-ANTIGEN; EXPRESSION; METALLOTHIONEIN; TRANSPORTER; APOPTOSIS; GENES (en)
http://linked.open.../riv/klicoveSlovo	CARCINOMA-CELLS CITRATE METABOLISM METALLOTHIONEIN T-ANTIGEN TRANSPORTER APOPTOSIS EXPRESSION EPITHELIAL-CELLS GENES DNA-DAMAGE
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[612EC2AF0DAC]
http://linked.open...i/riv/nazevZdroje	Metallomics
http://linked.open...in/vavai/riv/obor	CE
http://linked.open...ichTvurcuVysledku	6 (xsd:int)
http://linked.open...cetTvurcuVysledku	9 (xsd:int)
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	6
http://linked.open...iv/tvurceVysledku	Adam, Vojtěch Babula, Petr Gumulec, Jaromír Kizek, René Masařík, Michal Sztalmachová, Markéta Holubová, Monika Raudenská, Martina Axmanová, Martina
http://linked.open...ain/vavai/riv/wos	000338638000009
issn	1756-5901
number of pages	14 (xsd:int)
http://bibframe.org/vocab/doi	10.1039/c4mt00065j
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 27 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software